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ABSTRACT 
Multiple sclerosis (MS) is a progressive inflammatory and degenerative disease of the 
central nervous system (CNS). This thesis focuses on cognition in MS, with special 
emphasis on long-term magnetic resonance imaging (MRI) findings and cerebrosterol 
plasma levels.  
In study I, the effects of MS on a variety of cognitive aspects were evaluated 
longitudinally over an eight-year follow-up period in 31 patients who had been 
diagnosed as having relapsing-remitting MS, secondary progressive MS (SP-MS) or 
primary progressive MS. A selective pattern of decline was found at baseline in the 
whole group, with marked decline in information-processing speed (IPS). These 
deficits in IPS at baseline predicted further cognitive decline over the follow-up 
period. A differential pattern of cognitive decline over time was noticed in the 
subgroups, with the most pronounced decline in the SP-MS group; in these patients, 
the deterioration in visual IPS was clearly more marked than that in auditory IPS. A 
high disability score (on the expanded disability status scale; EDSS) during follow-up 
was associated with cognitive decline. These findings indicate that tests measuring 
IPS are especially strong predictors of cognitive decline over longer periods in 
patients with MS.                
In Study II, 25 patients with MS and 25 matched control participants were tested with 
a picture-naming test (Boston Naming Test; BNT) and a letter-word fluency test 
(using the letters FAS). In the BNT, the MS patients used less distinct descriptions 
and substitutions and had significantly more off-target substitutions than the control 
group. The MS patients were significantly less effective in using strategies for 
retrieval in the word fluency FAS test than the control participants. These results 
suggest that language function becomes impaired in MS, with semantically 
nonspecific naming responses and less effective use of strategies for retrieval in word 
fluency.   
In Study III, 22 MS patients were given tasks investigating IPS, covering the 
following aspects: cognitive (symbol digit modalities test; SDMT), sensory (visual 
and auditory reaction time tests), motor (finger-tapping speed test) and auditory 
interhemispheric transfer (verbal dichotic listening test; VDL). These parameters 
were related to the area of the corpus callosum in the brain (CCA), measured with 
MRI at baseline and at follow-up nine years later. The relative brain volume (RBV) 
and the T2 lesion load were taken into account. The results showed that the CCA, but 
not the RBV or the T2 lesion load, was associated with the SDMT score, and that the 
higher the annual rate of change in the CCA, the poorer the performance in the left 
ear VDL, with a subsequently more pronounced advantage in the right ear VDL. 
These results indicate that corpus callosum is related to a clearly cognitive 
component, rather than a sensory-motor component.       
Study IV analyzed the relationships between cognitively demanding information 
processing (measured with the SDMT), clinical status (EDSS), plasma cerebrosterol 
  
24OHC levels, and MRI-normalized measurement of RBV, grey and white matter 
volumes, and ventricular cerebrospinal fluid volume in a cross-sectional sample of 21 
MS patients. The results showed that slow IPS in SDMT was related to 
neurodegeneration, particularly loss of grey matter volume, and high cerebrosterol 
plasma concentrations, reflecting membrane turnover in the CNS. Poor EDSS was 
associated with high plasma cerebrosterol levels, which is hypothetically a biomarker 
of MS progression. 
Conclusions: Deterioration in IPS seems to be a central aspect of cognitive decline in 
MS. Slow IPS occurs already at an early phase in the disease and predicts long term 
cognitive decline. The MS patients have less effective strategies for lexical 
substitution and retrieval than healthy persons. The poor lexical processing in the MS 
patients could putatively be due to slow IPS, especially in the markedly speed 
demanding word fluency test. CCA in contrast to RBV and the T2 lesion load, 
appears to be exclusively related to a cognitively demanding IPS task but not to 
sensory-motor speed tasks, which suggests that CC is especially important for 
cognitive speed processes. Slow IPS seems to be primarily associated with low grey 
matter volume and high plasma concentration level of cerebrosterol while disability 
appears to be related to high plasma level of cerebrosterol. Since there were no 
interaction between cerebrosterol and the neurodegenerative predictors, it is putative 
that the cytotoxic properties of the cerebrosterol independently could cause neuronal 
cell death and thereby affect IPS independently of neurodegeneration.             
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1 THESIS SUMMARY – MAIN SECTION 
 
1. GENERAL BACKGROUND 
1.1 Multiple sclerosis: Introduction 
Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory, neurodegenerative, 
demyelinating neurological disease of the central nervous system (CNS). It has 
unknown etiology and a duration of many years. From a historical perspective, there 
are early descriptions of neurological symptoms and the subsequent development of 
persisting dysfunction which appear to describe MS; for example, in the diary written 
by the English aristocrat Augustus D’Este during the period 1830-40 (Fredrikson and 
Kam-Hansen 1989; Landtblom et al. 2010). In 1860 Jean-Martin Charcot identified 
and named the disease “sclerose en plaques disseminées”. He noted the association 
between loss of the fatty insulation layer composed of myelin around the nerve fibers 
and the patterns of neurological impairment, and he suggested diagnostic criteria 
(Charcot´s triad) based on the occurrence of dysarthria, ataxia and tremor (Charcot 
1877). Later research using improved diagnostic techniques such as magnetic 
resonance imaging (MRI) has confirmed Charcot's clinical findings and added to our 
understanding of MS. 
 
1.2 Epidemiology 
MS primarily strikes young and middle-aged adults aged 20-40 years (Weinshenker 
et al. 1989). The average age of disease onset is around 30 years (Sibley 1990; 
Weinshenker et al. 1991). In rare cases, the onset of MS can occur early in childhood. 
MS is two to three times as common in women as in men (Goodin 2014). The 
prevalence of MS varies with the geographic position, with the highest frequency in 
temperate climate zones at southern or northern latitudes, such as in Western Europe. 
Scotland and the Outer Hebrides, in particular, have a high prevalence, which can be 
up to 300 cases per 100000 people. England and Wales have rates varying from 74 to 
112 per 100000 (Rejdak 2010). Sweden also belongs in these areas of high prevalence 
(Andersen 2012). Interestingly, some ethnic groups living in high prevalence areas 
appear to be resistant to MS, for example some of the First Nations people of western 
Canada (Rejdak 2010). 
 
1.3 Etiology 
The etiology of MS seems to be complex and multifactorial. It appears that a genetic 
factor contributes to the etiology. First-degree relatives of a person with MS are at 
higher risk of contracting the disease than the general population. Monozygotic twins 
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are reported to have a higher risk of contracting MS than dizygotic twins (Dyment et 
al. 2004; Baranzini et al. 2010). Individuals who live with MS patients but are not 
genetically related to them are at no higher risk than the general population. It has 
been found that the human leukocyte antigen (HLA) system can bind body-specific 
proteins in some human tissue types, thereby contributing to the autoimmune 
activation of T-cells in MS (Fagius et al. 2007). The HLA region on chromosome 6 is 
associated with MS and the presence of HLA-DR 2 in people living in northern 
Europe is connected with the disease (Dyment 2004). There are indications that the 
CYP27B1 gene is also associated with MS,  by encoding the vitamin D-activating 1-
alpha hydroxylase enzyme (Ramagopalan 2011).  
Environmental factors are also part of the etiology of MS. It has been observed that 
people who migrate before puberty from areas at high risk of MS to areas at low risk 
are less likely to contract the disease (Kurtzke 1993). Such observations have given 
rise to a viral or infective hypothesis.  However, animal studies have failed to isolate 
the causative organism, or to transfer the disease to other animals. The focus has been 
on the Epstein-Barr virus (EBV) as a possible viral trigger of MS. EBV is a common 
cause of mononucleosis which has a similar geographic distribution to MS. In a case-
control study, Hernan et al. (2001) showed that patients who had previously 
developed mononucleosis had an increased prevalence of MS. Ascherio et al. (2001) 
demonstrated in a prospective study that individuals with symptomatic EBV infection 
or with stronger antibody responses to EBV were more likely to develop MS than 
those without. Despite these findings, no causal relationship has been established 
between MS and EBV. Human herpesvirus 6 and Chlamydophyla pneumoniae have 
also been suggested as possible causative agents of MS (Swanborg et al. 2003). 
Sunlight exposure and vitamin D levels are environmental factors that appear to be 
important etiological factors in MS, because of the relationship between geographical 
differences in sunlight exposure and the association between latitude and the 
prevalence of MS around the world, and the effects of sunlight on serum vitamin D 
levels in association with the immunomodulatory effect of vitamin D on the 
homeostasis of T-cells (Correale et al. 2009). Epidemiological research has also 
identified a history of smoking as an environmental risk factor for MS (Handel and 
Ramagopalan 2011).  
It has been hypothesized that environmental factors could interact with the genes via 
epigenetic mechanisms to regulate gene expression, thus modulating the disease 
presentation (Burell et al. 2011, Huynh et al. 2013).  
 
1.4 Pathophysiology and biochemistry of MS 
It has been hypothesized that the pathogenesis of MS is related to exposure of the 
patient to an environmental agent during childhood which triggers epigenetic 
mechanisms, thereby inducing potentially auto-reactive T-cells. These potentially 
auto-reactive T-cells are activated after a period of latency by a systemic trigger (such 
as infection), are attached to the internal wall of the blood vessel by the adhesion 
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molecules on their surface, and then pass through the blood-brain barrier (BBB) from 
the blood into the brain tissue, producing proinflammatory cytokines and initiating a 
local cell-mediated immune reaction.  
Myelin and neuronal antigens are then released and the antigens cross from the brain 
tissue across the BBB to be presented to T-cells as foreign, thereby inducing activated 
auto-reactive T-cells which proliferate; the receptors on these fit the proteins from the 
myelin sheath. These activated proliferated T-cells go through the BBB and come in 
contact with protein fragments of myelin presented by the receptors on HLA 
molecules, whereby they are further activated to produce cytokines which attract 
more activated T-cells and activate microglia, astrocytes and endothelial cells, giving 
rise to more proinflammatory cytokines such as interleukin (IL)-1 and tissue necrosis 
factor-α. These cytokines upregulate the adhesion molecules in the endothelium at the 
BBBand, together with chemo-attractant cytokines (chemochines), they reinforce the 
recruitment of T-cells. In this context, B-cells produce auto-antibodies which bind to 
the myelin and contribute to its destruction. These auto-antibodies also facilitate the 
destruction by macrophages of the myelin sheath (Fagius et al. 2007; Rejdak et al. 
2010). The macrophages secrete an enzyme (protease) which breaks down the myelin 
(Smith 2001). The auto-antibodies and other cytotoxic substances such as reactive 
oxygen, perforin and granzyme boost the effects of the pro-inflammatory cytokines 
(Lord et al. 2003; Morales et al 2006) and cause the death of myelin-producing 
oligodendrocytes and demyelination, resulting in conduction block.  
At the same time, suppressor T-cells are producing immunomodulatory cytokines 
such as IL-4 and transforming growth factor-β, and neuroprotective neurotrophic 
factors such as nerve growth factor (NGF) and brain-derived neurotrophic factor 
(BDNF), which mediate cell survival and proliferation in the CNS (Kalinowska-
Lyszczarz and Losy 2012), thereby reducing the inflammation and helping the 
oligodendrocytes to survive and proliferate. The plasticity resulting from these 
mechanisms allows some remyelination and functional recovery to take place. 
Persistent demyelination does, however, cause axonal loss (Rejdak et al. 2010).  
The neuron-specific enzyme Cyp46A1(24-s hydroxylase) oxidizes cholesterol from 
the destroyed brain tissue into the water-soluble metabolite cerebrosterol (24-
hydroxycholesterol; 24OHC), which is a steroid acid that freely passes the BBB, and 
the degraded cholesterol is thus removed from the CNS (Lütjohann et al. 2003). 
Leoni and Caccia (2011) reported that levels of plasma cerebrosterol were correlated 
with brain atrophy in relapsing-remitting MS (RR-MS) and primary progressive MS 
(PP-MS) patients. Karrenbauer et al. (2006) demonstrated a negative correlation 
between the cerebrosterol-cholesterol ratio in plasma and the volume of T2-weighted 
lesions in RR-MS and PP-MS patients, and a positive correlation between the 
cerebrosterol-cholesterol ratio and the volume of T1-weighted hypointense lesions in 
RR-MS patients. Increased levels of plasma cerebrosterol were found in MS patients 
with inflammatory active gadolinium-enhancing T2 lesions but not in MS patients 
without this type of lesion (Leoni et al. 2004). According to Leoni and Caccia (2013), 
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focal inflammatory activity could be associated with increased turnover of cholesterol 
in the brain.  
Grey matter lesions are different from white matter lesions in that they have fewer 
inflammatory characteristics such as infiltration by macrophages and lymphocytes, 
which suggests a lack of an adaptive immune response (Rejdak 2010). The process of 
cerebral atrophy in MS is not fully understood, but it is assumed that neuro-
inflammation triggers the cerebral degeneration (Amato 2004;Fagius et al. 2007).  
 
1.5 Diagnosis of MS  
The diagnosis of MS is clinical. In 1982, the Poser Committee (Poser et al. 1983) set 
up criteria aiming to ensure that trials and research protocols would only include 
patients with true MS. The McDonald criteria, which were introduced in 2001, 
revised in 2005, and revised again in 2010, included evidence from new MRI 
techniques and simplified the diagnosis of PP-MS, making the role of spinal cord 
lesions clearer; these criteria are now the main diagnostic standard for MS (Polman et 
al. 2011).     
According to the Poser criteria, MS can be definite or probable. Within these, it can 
be clinically definite/probable or laboratory-supported definite/probable.  
The criteria for clinically definite MS are: 1. at least two attacks and clinical evidence 
of two separate lesions; or 2. at least two attacks and clinical evidence of one lesion 
plus paraclinical evidence [including computed tomography (CT), MRI, evoked 
potential, hyperthermia challenge, and urodynamic studies] of another separate lesion. 
The two attacks must be located in different parts of the CNS and each of them must 
last for at least 24 hours and be separated by a period of at least one month. 
Occasionally, symptoms which are reliable and adequate for locating an MS lesion 
can be accepted instead of clinical evidence.  
Criteria for laboratory-supported definite MS include: 1. at least two attacks and 
either clinical or paraclinical evidence of one lesion plus a positive cerebrospinal fluid 
(CSF; i.e. elevated IgG index or oligoclonal bands); 2. one attack and clinical 
evidence of two separate lesions plus a positive CSF; or 3. one attack and clinical 
evidence of one lesion plus paraclinical evidence of another separate lesion and a 
positive CSF. The two attacks must appear in different parts of the CNS and each 
must last at least 24 hours and be separated by at least one month. One of the attacks 
must involve a different part of the CNS from that demonstrated by the clinical or 
paraclinical evidence. 
Criteria for clinically probable MS include: 1. at least two attacks and clinical 
evidence of one lesion; 2. one attack and clinical evidence of two separate lesions; or 
3. one attack plus clinical evidence of one lesion and paraclinical evidence of another 
separate lesion. The two attacks must involve separate parts of the CNS.  
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Criteria for laboratory-supported probable MS are at least two attacks plus a positive 
CSF. The two attacks must be associated with different parts of the CNS and be 
separated by at least one month, and each attack must have a duration of at least 24 
hours.  
The revised McDonald criteria (2010) for a diagnosis of MS are:  
1. Two or more attacks (or relapses) and two or more objective clinical lesions. No 
additional information is needed. 
2. Two or more attacks and one objective clinical lesion plus dissemination of the 
disease in space, as demonstrated by MRI, or a positive CSF plus two or more MRI 
lesions consistent with MS, or a further clinical attack involving a different site.  
3. One attack and two or more objective clinical lesions plus dissemination of the 
disease in time, as demonstrated by MRI or a second clinical attack. 
4. One attack and one objective clinical lesion (monosymptomatic presentation) plus 
dissemination of the disease in space, as demonstrated by MRI, or a positive CSF 
plus two or more MRI lesions consistent with MS, as well as dissemination in time, 
as demonstrated by MRI or a second clinical attack. 
5. Insidious neurological progression suggestive of MS. One year of disease 
progression must be retrospectively or prospectively observed and there must be at 
least two of the following: a positive brain MRI [i.e. nine T2 lesions or four or more 
T2 lesions with positive visual evoked potential results]; a positive spinal cord MRI 
(i.e. two focal T2 lesions); a positive CSF. 
 
1.6 Clinical presentation 
The clinical presentation and course of MS is highly variable and individual (Lublin 
and Reingold 1996; O´Connor  2002). In 85% of MS patients, the first indication of 
MS onset involves an episode of neurological disturbance (called the clinically 
isolated syndrome; CIS) (Miller et al. 2012). The CIS suggests the possibility of MS 
and usually manifests as a lesion in the optic nerve (optic neuritis), spinal cord or 
cerebellum. MS can also present as cognitive changes, seizures or encephalopathy. 
Fifty to seventy percent of adults who have a CIS have multiple asymptomatic white 
matter lesions in the brain (Miller et al. 2012).  
According to consensus reached late last century, there are four main types of MS 
(Lublin and Reingold 1996).These are a. RR-MS, which is characterized by clearly 
defined disease attacks with sequelae and full or partial recovery with periods 
between disease attacks characterized by a lack of disease progression; b. PP-MS, 
which is characterized by disease progression from the onset with occasional plateaus 
and temporary minor improvements; c. secondary progressive MS (SP-MS), which 
occurs after an initial relapsing-remitting course and is characterized by progression 
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with or without occasional relapses, minor remissions and plateaus; and  d. 
progressive relapsing MS (PR-MS), which is characterized by a progressive disease 
course from the onset, with clear acute relapses, with or without  full recovery, and 
periods between relapses characterized by continuing disease progression. PR-MS is 
rare. It has, in fact, been questioned whether PP-MS and PR-MS are truly different, 
because their natural histories are so similar (Kremenchutzky 1999).  
The typical pattern of clinical progression in MS is that an initial phase of RR-MS, in 
which recovery from each relapse is incomplete so that the symptoms accumulate, 
develops into a progressive disease course (SP-MS). In a long-term geographically 
based study, Weinshenker et al. (1989) demonstrated that approximately 50% of 
patients with RR-MS switch to SP-MS during the first 10 years after disease onset 
and around 90% of RR-MS patients develop SP-MS within 25 years.                    
The term benign MS is used to describe a subtype of RR-MS which is characterized 
by minor progression of disability [according to the expanded disability status scale 
(EDSS) (Kurtzke 1983)] 10 years after the disease onset (McAlpine 1961). Malignant 
MS is characterized by rapid disease progression, with development of significant 
disability or death within a few months of the onset of the disease (Lublin and 
Reingold 1996). 
Long-term studies have provided evidence that patients reach the stage at which 
walking is impaired within a median of 10 years, the stage at which there is need of 
unilateral support while walking within a median of 15-20 years, and the stage at 
which they can walk only a few steps within a median of 30 years (Weinshenker and 
Ebers 1987). 
Life expectancy in patients with MS varies with different studies. An analysis of 
registry data from Vancouver, British Columbia, and London, Ontario, Canada, 
demonstrated that for most age groups, life expectancy is shortened by six to seven 
years (Sadovnick 1992). In a study of patients attending the MS clinics in Vancouver 
between 1972 and 1988, 47.1% died from complications of MS and 28.6% of the 
remaining deaths were due to suicide (Sadovnick et al. 1991).  
It is generally accepted that the following clinical and demographic factors can 
negatively affect the prognosis of MS: older age at onset (>40 years); motor, 
cerebellar, sphincter or multiregional symptoms; frequent relapses during the first 
years of the disease; a short interval between the first two attacks; incomplete 
remissions; fast progress of disability; and a short time from the onset of the disease 
to the start of the progressive phase (O´Connor 2002).   
 
1.7 Clinical measures of disease progression 
1.7.1 Clinical evaluation of disability  
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The commonly used clinical measures of MS disability are the EDSS (Kurtzke 1983) 
and the multiple sclerosis severity score (MSSS) (Roxburgh et al. 2005). 
The EDSS is based on eight functional systems: pyramidal, cerebellar, brainstem, 
sensory, bowel and bladder, visual, cerebral and “other”. Each of these functional 
systems is rated during neurological examination on a 0-to-5 or 0-to-6 scale, except 
for the “other” functional system, which is scored zero or one. The functional system 
ratings give a total score out of 10, in increments of 0.5. This total score is named the 
EDSS score. An EDSS score of 0 signifies normal neurological status. An EDSS 
score of 10 signifies death. The EDSS rates the level of disability, focusing especially 
on motor function measured as the ability to walk. Thus, the EDSS puts much 
emphasis on the pyramidal tract and brain stem function but pays relatively little 
attention to mental processes such as mood and cognition. Although there is a high 
prevalence of mood disorders in patients with MS, this affective dysfunction is not 
recognized by the EDSS, which can erroneously give the impression that the MS 
patient is in good overall emotional condition (Feinstein 1997). With respect to 
cognitive dysfunction, the cerebral functional system rates cognitive impairment on a 
scale of 2 (mild), 3 (moderate), 4 (marked) or 5 (demented). Thus, it is possible for a 
demented MS patient to have a total EDSS score of 5.0, signifying an only moderate 
degree of disability, which would of course be misleading. Another weakness of the 
EDSS scale is that it is ordinal and not linear and is thus not sensitive to changes in 
clinical status over time. Furthermore, EDSS has a limited ability to discriminate 
between individuals in terms of the extent of their disability (Hobart et al. 2000). 
The MSSS was developed from a database of 9892 MS patients by applying an 
arithmetic method to correct each patient's EDSS score for disease duration; the 
extent of each patient´s disability was compared with the distribution of disability 
scores in patients with the same disease duration to create a reference table 
(Roxburgh et al. 2005). According to Roxburgh et al., the MSSS has the advantage of 
detecting different rates of disease progression more efficiently than the EDSS. The 
MSSS can be used for comparing groups of patients, but disease fluctuations prevent 
its use for predicting future disability for individuals.   
 
1.7.2 Radiological measures in MS 
MRI-based measures are important for the clinical diagnosis and management of MS 
and for gaining an understanding of the disease mechanisms (Filippi and Rocca 
2007). The conventional MRI measures include measurement of brain atrophy and 
lesions; hypointense T1 lesions and hyperintense gadolinium-enhancing T2 lesions 
indicate active inflammation. The extent of the T2 lesions in the CNS is of clinical 
importance early in the MS course and has a prognostic value in predicting 
transformation from a CIS to RR-MS (Barkhof et al. 1997)). T2 lesions are more 
common in the white matter than in the grey matter on conventional MRI and are 
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frequently located in periventricular white matter, the inner surface of the corpus 
callosum, the juxtacortical grey-white junction, the infratentorial brain regions, and 
the spinal cord (Neema et al. 2007). Kutzelnigg et al. (2005) have demonstrated that 
white matter lesions are predominantly focal and periventricular to start with, 
changing with time to being more subtle and diffuse; these changes are accompanied 
by a substantial increase in the extent of demyelination in the grey matter. The white 
matter T2 lesions can disappear to a variable extent, which indicates potential for 
repair (Meier et al. 2007). Despite the importance of conventional MRI for 
understanding the pathophysiology of MS on a macroscopic level, these lesion 
measures are not specific enough to detect any underlying microscopic pathology 
which might affect the white and grey matter, and are weak in comparison with the 
EDSS status (Neema et al. 2007). In a study in which brain slices from chronic MS 
patients were analyzed histopathologically with both conventional and quantitative 
MRI, Seewann et al. (2011) found that cortical lesions which are visible with 
conventional MRI are associated with a higher total lesion load, and concluded that 
when cortical lesions are detected with MRI, they represent only a small part of the 
pathology, meaning that the essential underlying pathology is missed. Thus, the 
macroscopic lesions visible with MRI may actually extend further in normal-
appearing brain tissue.    
T1-hypointensive lesions (so-called black holes), primarily seen in the supratentorial 
cerebral regions, usually begin as gadolinium-enhanced active inflammatory lesions. 
Sailer et al. (2001) demonstrated in a prospective study that there was a correlation 
between changes in the T1 lesion volume and progressive cerebral atrophy, whereas 
no such association was seen between the T2 lesion volume and atrophy; they 
concluded that there may be a direct link between T1 hypointensive abnormalities and 
cerebral atrophy. 
The mechanisms causing atrophy are not fully understood. It has been assumed that 
brain atrophy is due to cortical inflammatory pathology, demyelination, axonal loss, 
and neuronal apoptosis (Peterson et al. 2001). Studies have suggested that axonal loss 
could be independent of the mechanisms causing demyelination, that it is caused by 
an abnormal glial-axonal interaction, and that it can occur in the absence of 
inflammation (Bitsch et al. 2000; Garbern et al. 2002). These findings have given 
support to the assumption that although cortical atrophy can be associated with white 
matter inflammation, an independent process causing atrophy could also be present 
(Amato 2004). Atrophy in the CNS affects the infratentorial areas as well as the 
supratentorial areas such as the cortical (Portaccio et al. 2006) and subcortical regions 
(Lin et al. 2008). Radiological measures of cerebral atrophy include assessment of the 
volume of grey matter, the volume of ventricular CSF, and the RBV normalized brain 
volume i.e. brain parenchymal fraction. Grey matter atrophy, which is recognized as 
an marker of disease progression in MS (Fisher et al. 2008), precedes white matter 
atrophy because the rate of atrophy is higher in the grey matter than in the white 
matter in the early stages of MS (Dalton et al. 2004). Grey matter atrophy can occur 
as early as in the CIS and in the initial stages of RR-MS (Dalton et al. 2004), and is 
reported to be significantly correlated with disability (Fisher et al. 2008). Fisher et al. 
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(2008) demonstrated that the rate of grey matter atrophy accelerates at the point 
where RR-MS switches to SP-MS. The new ultra-high-field MRI technology, which 
uses magnets of 3.0 tesla or more, offers greater sensitivity in detecting lesions and 
the opportunity of further exposing the underlying cortical pathology. In comparison 
with conventional MRI with lower field strengths, high-field MRI can detect more T2 
and T1 lesions in the early stages of the disease with better precision (Neema et al. 
2007). Other new MRI techniques include magnetization transfer imaging (MTI) and 
diffusion tensor imaging (DTI). MTI was developed for detecting disease activity and 
monitoring disease progression in MS. It can detect a decrease in the exchange of 
protons, which appears in pathological brain tissue, as a decreased magnetization 
transfer ratio, which is assumed to primarily mirror demyelination and axonal loss. 
DTI detects alterations in the direction, randomness and velocity of water movement 
in the tissue, mapping the diffusion of water three-dimensionally, calculating the 
magnitude, degree and orientation of diffusion anisotropy, and thus measuring 
demyelination and loss of axonal integrity (Neema et al. 2007). 
 
1.7.3 Cognitive impairment in MS 
The prevalence of cognitive impairment in MS is reported to be between 40 and 70% 
(Chiaravalloti and DeLuca 2008). Cognitive dysfunction is often seen early in the 
disease course (Nocentini et al. 2006) and is present in all MS subtypes (Portaccio et 
al. 2009). It has been reported in the CIS (Khalil et al. 2011). Kujala et al. (1997) 
demonstrated that incipient cognitive decline in MS tends to worsen over time, but 
that normal cognitive functioning can remain intact. Cognitive impairment increases 
with long disease durations and the development of a progressive disease course 
(Achiron et al. 2005), and is generally more severe in SP-MS than in RR-MS (Beatty 
et al. 1989). Studies comparing PP-MS and SP-MS patients have generally found 
greater cognitive dysfunction in the SP-MS group (Chiaravalloti and DeLuca 2008). 
The cognitive domains most frequently impaired in MS are information processing 
speed (IPS) and memory (Rao et al. 1991). Impairment is also often seen in executive 
functioning (EF) (Lazeron et al. 2004). Crystallized knowledge and language 
comprehension are, in contrast, relatively resistant to MS (Bobholz and Rao 2003). 
IPS is associated with the ability to keep information in the working memory (WM) 
and the speed with which it is simultaneously manipulated and modified. Thus 
deficits in WM and IPS affect each other. Studies in large populations of MS patients 
have shown that the frequency of deficits in IPS is higher than that in WM, especially 
in SP-MS patients (DeLuca et al. 2004). The performance of MS patients in tests 
investigating IPS has been reported to decline more rapidly than that in tests 
measuring other cognitive domains (Denney et al. 2008). The symbol digit modalities 
test (SDMT; oral form) and the paced auditory serial addition test (PASAT) are 
commonly used for measuring IPS (Lezak 1995). An expert committé (BICAMS) of 
members representing the main cultural groups has recommended the SDMT as the 
test of IPS. The reason for this recommendation was that it is congenial for both 
patient and assessor, has good psychometric properties and clinical validity expressed 
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by an association with employment status and is also satisfactory validated against 
conventional brain MRI parameters as well as fMRI (Langdon et al. 2012). In a 3-
year longitudinal study, Amato et al. (2010) found that poor performance in the 
SDMT at baseline predicted further cognitive decline with time.    
Attention is associated with both IPS and WM. MS patients have an impaired ability 
in complex attention tasks involving sustained attention and divided attention, with 
the focus on several tasks simultaneously (McCarthy 2005).  
Long-term memory is reported to be impaired in 40-65% of MS patients (Rao et al. 
1993). Recent research has demonstrated that a poor performance in long-term 
memory tasks in MS patients is due to difficulties in the initial encoding of 
information and not primarily to dysfunctional retrieval of information (Thornton et 
al. 2002). MS patients need to put more effort into repetitions to reach learning 
criteria but, when they have done that, their ability to recall and to recognize the 
initial information is as good as in healthy controls (DeLuca et al. 1998). The Rey 
auditory verbal learning test (RAVLT) is widely used for assessing memory (Lezak 
1995). When evaluating memory function in MS patients, it is important to keep in 
mind that their performance in memory tests could also be affected by deficits in EF 
and IPS. 
The EFs are associated with the frontal lobes of the brain; they include complex goal-
directed behavior (planning), initiation and inhibition of behavior, shifting of 
behavior (flexibility), updating (WM), and anticipating outcomes by simulation 
(Baddeley 1986; Filley 2000). Executive dysfunction does occur in MS patients, but 
less frequently than deficits in IPS and memory (Bobholz and Rao 2003). In a 
community-based sample, Drew et al. (2008) found that 17% of MS patients had 
deficits in EFs, including fluency, set-shifting (moving attentional focus) and 
inhibition. Tests for fluency are common among tests measuring EFs; for example, 
the controlled oral word-association test (COWAT), which measures phonemic 
(word) fluency, and the category test, which measures semantic fluency (Lezak 1995; 
Spreen and Strauss 1998). In a quantitative review of 35 studies, Henry and Beatty 
reported that increased neurological disability or a progressive MS course were 
associated with deficits in tests of phonemic and semantic fluency.   
 
1.7.4 Cognition in MS in relation to MRI characteristics 
MRI results appear to be correlated with cognitive functioning in MS patients, and 
can be used to assist in the assessment of cognitive function (Filippi et al. 2010). It 
has been demonstrated that MS patients with greater lesion loads are more cognitively 
impaired than those with less of a lesion burden (Swirsky-Sacchetti et al. 1992). 
Cortical lesions and atrophy predict cognitive dysfunction independently of each 
other, leading to the assumption that they represent two different processes (Calabrese 
et al. 2009). However, in cross-sectional and longitudinal studies, brain atrophy 
appears to have a stronger correlation with cognitive performance than T2 and T1 
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lesion volumes, which have only a modest correlation with functioning in cognitive 
tests (Rovaris et al. 2006). Summers et al. (2008) showed that brain atrophy early in 
the clinical course predicts cognitive impairment several years later in RR-MS 
patients. The width of the third ventricle is reported to be especially strongly 
associated with cognitive dysfunction (Benedict 2006). Atrophy in the white matter 
has been shown to affect cognitive functions that are dependent on the rapid transfer 
of information, such as IPS and WM (Sanfilipo et al. 2006). Loss of volume in the 
white matter structure corpus callosum due to atrophy is reported to reduce attention 
and IPS measured by the PASAT (Lin et al. 2008). Yaldizli et al. reported that 
atrophy of the posterior segment of corpus callosum in MS patients, correlated with 
decline in IPS and verbal fluency. Calabrese et al. (2010) found widespread cortical 
thinning in MS patients with mild cognitive impairment, indicating that cognitive 
dysfunction could be associated with an underlying global pathology. Grey matter 
atrophy is related to impairment of verbal memory, verbal fluency and attention 
(Amato et al. 2004; Benedict et al. 2006). It has been reported that atrophy in the 
thalamus in MS patients is a strong predictor of cognitive dysfunction. Hippocampal 
atrophy in MS patients is associated with dysfunction in memory encoding and 
retrieval (Sicotte et al. 2008). Tekok-Kilic (2007) showed that left frontal atrophy in 
MS patients is related to deficits in verbal memory performance while right frontal 
atrophy is associated with dysfunction in visual memory and WM. Studies 
concerning the relationship between functional anisotropy measured by DTI and 
cognitive performance in MS patients have given contradictory results (Chiaravalloti 
and DeLuca 2008). 
 
1.7.5 Cognition in MS and functional MRI (fMRI) 
Studies of MS and cognition using functional imaging techniques have mainly 
focused on WM, attention and EFs (Chiaravalloti and DeLuca 2008). In many fMRI 
studies, cortical activation associated with rising blood-oxygenation levels has been 
found in similar regions in MS patients and controls, but the magnitude of activation 
was higher in the MS group. This has been explained as the result of recruitment of 
other cortical networks as a compensatory mechanism (Filippi et al. 2004). This 
increase in activity has also been shown in a study of MS patients with normal 
performance levels in cognitive tests and in accordance with the hypothesis of 
compensatory recruitment of cortical networks, the cognitive performance level 
declines when the increased activation is no longer sufficient to compensate for the 
decreased cortical neuronal integrity (Langdon 2011). Studies of cortical activation in 
relation to working memory tasks using fMRI, have found that the same cortical 
regions are activated in MS patients and healthy persons but the magnitude of 
activation is higher in MS patients than in normal controls (Wishart et al. 2004). 
Penner et al. (2003) reported that MS patients with mild cognitive impairment had 
stronger activation than controls in the right dorsolateral prefrontal cortex, right 
superior temporal gyrus, right lateral cerebellum, left angular gyrus and bilateral 
inferior parietal cortex, during attention tasks. Furthermore, they found that severely 
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cognitively impaired MS patients also had higher activation in the left inferior parietal 
lobe than the control group. In an fMRI study focusing on a task requiring planning, 
which is an aspect of EF, Lazeron et al. (2004) found similar levels of activation in 
the bilateral frontal and parietal lobes in MS patients and healthy normal controls. 
 
1.7.6 Cognition in MS in relation to neurochemistry 
The relationship between brain neurochemistry and cognitive dysfunction in MS is 
relatively unexplored in comparison with the association between cognitive deficits 
and morphological brain MRI characteristics. However, recent findings have 
provided evidence suggesting an association between the lack of neuroprotective 
NGF and cognition in MS. Thus, it has been reported that poor performance in RR-
MS patients in a spontaneous word list generation task and a memory recall task was 
related to low concentrations of the neurotrophin beta-NGF in plasma (Kalinowska-
Lyszczarz et al. 2012). Patanella et al. (2010) demonstrated a correlation between low 
levels of BDNF and poor performances in a speeded divided-attention test and a 
visual scanning test.  
It is known from previous studies that levels of cerebrosterol are positively correlated 
with brain atrophy (Leoni and Caccia 2011) and the presence of T2-weighted lesions 
(Karrenbauer et al. 2006) in RR-MS and PP-MS, which evokes the question of 
whether they are also associated with cognitive dysfunction in MS. In an 
epidemiological study, Hughes et al. (2012) demonstrated that healthy people with 
high cerebrosterol levels and high 24OHC/27OHC ratios were at greater risk of 
developing cognitive impairment over 8 years' follow-up. Leoni & Caccia (2013 and 
2014) reported a correlation between cognitive tests (one was SDMT measuring IPS) 
and decreased cerebrosterol levels in patients with Huntington´s disease. However up 
to now the relationship between cognitive dysfunction and level of plasma 
cerebrosterol has not been studied in MS patients and therefor deserves attention. 
 
1.7.7  Cognition in MS in relation to genetics 
Relatively few studies have investigated the relationship between genetics and 
cognitive functioning in MS. However, the few available studies indicate a possible 
link between the apolipoprotein E (APOE) epsilon-4 allele and cognitive functioning 
in MS patients (Ghaffar and Feinstein 2009). Koutsis et al. (2007) and Shi et al. 
(2008) reported an association between carriage of this allele and impairment of 
verbal memory. Aspects of genetic protection against cognitive deficits have also 
been reported; Weinstock-Guttman et al. (2011) found that MS patients with a variant 
of brain-derived neurotrophic factor (BDNF) gene were more protected against visual 
memory deficits than MS patients who did not have this gene variant.       
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1.7.8 Cognition in MS in relation to demographic variables 
Male MS patients appear to show cognitive deficits to a greater extent than women 
(Beatty and Aupperle 2002; Schoonheim et al. 2014). MS does not interact with age, 
and does not affect normal cognitive deterioration with age (Bodling et al. 2009). 
Thus, MS patients go through the same process of cognitive aging as healthy adults. 
Higher education levels have been shown to protect against cognitive decline in MS. 
against declines in IPS (Benedict et al. 2010;Sumowski et al. 2009).  
 
1.7.9 Cognition in MS in relation to disease variables 
Studies of the relationship between disability (measured by the EDSS) and cognitive 
decline have given contradictory results (Heaton et al. 1985; Rao et al. 1991). In these 
studies, disease duration can be a confounding factor, since it is associated with 
greater physical disability and the development of a progressive disease course, which 
is associated in turn with more pronounced cognitive decline. Chiaravalloti and 
DeLuca (2008) conclude in their systematic review that cognitive impairment is only 
mildly associated with physical disability.   
 
1.7.10 Cognition in MS and fatigue 
Fatigue is reported to affect up to 87% of patients with MS (Krupp et al. 1988). The 
findings concerning effects of self-reported fatigue on cognitive functioning have 
yielded ambiguous results. Some studies have not found any significant relationship 
between self-reported fatigue and objective performance on cognitive tests (Bailey et 
al. 2007). However, declines in sustained task performance have been reported in MS 
patients compared with healthy controls (Schwid et al. 2003). 
 
1.7.11 Cognition in MS and depression 
The prevalence of depression in MS patients is reported to be between 27% and 54% 
(Joffe et al. 1987;Minden et al. 1987). Depression affects a variety of cognitive 
functions, including WM and IPS (Arnett et al. 1999).  
 
1.7.12 Cognitive functioning and pharmacological treatment  
There are limited and inconsistent data concerning the effects of disease-modifying 
medications on cognitive functioning in MS. Interferon beta-1a is reported to have a 
beneficial effect on IPS and memory. Fisher et al. (2000) and Pliskin et al. (1996) 
showed that interferon beta-1b also has a mild positive effect on performance in a 
visual memory task. However, there is no evidence for any beneficial effects 
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associated with glatiramer acetate, natalizumab, or fingolimod on cognitive function 
in MS patients (Amato et al. 2013).   
 
1.7.13 Cognition in relation to cognitive training and rehabilitation 
There are relatively few studies on the treatment of cognitive deficits using training 
and rehabilitation. The rehabilitation programs which have been developed are 
intended to improve attentional deficits, communication skills and memory 
impairment (Chiaravalloti and DeLuca 2008). In a study of MS patients with 
moderate-to-severe memory impairment, Basso et al. (2006) found that a self-
generated memory technique in which the target word was encoded by actively 
generating it from a cue (first letter) was a more effective way of learning than 
traditional didactic encoding. Similarly, a spaced learning technique with 5-minute 
breaks between each learning trial resulted in better acquisition of everyday 
functional tasks than a traditional learning model without such intervals in a study of 
MS patients and healthy controls (Goverover et al. 2008). There are methodological 
limitations in many of the studies focusing on cognitive training and rehabilitation; 
for example, the use of a qualitative rather than a quantitative research design, 
reliance on case studies, lack of control groups, and a follow-up period that is too 
short (Amato et al. 2013; Chiaravalloti and DeLuca 2008). According to a Cochrane 
review by Otajärvi-Rosti and Hämäläinen (2014) the interventions and outcome 
measures in studies concerning neuropsychological rehabilitation in MS are 
heterogenous, which makes it difficult to compare these reports. When evaluating all 
twenty studies together Otajärvi-Rosti and Hämäläinen found low-level evidence for 
that neuropsychological rehabilitation improves cognition in MS. Nevertheless when 
they analysed the studies one by one, 18 of these studies appeared to have a positive 
effect on cognition. Thus cognitive training improved memory span and working 
memory. When cognitive training was combined with other neuropsychological 
rehabilitation methods such as learning compensatory strategies, attention, immediate 
verbal memory and delayed memory were improved.   
 
1.7.14 Cognition in relation to daily living and quality of life (QoL) 
MS patients with cognitive deficits experience difficulties performing everyday 
activities. Goverover et al. (2006) reported that performance on tests measuring IPS 
was associated with the level of daily life activities that demanded quick responses. 
Furthermore, there was a correlation between poor QoL and cognitive dysfunction 
(Cutajar et al. 2000). Cutajar et al. reported that poor performance in frontal-lobe-
related executive tasks, measured using the Luria frontal lobe syndrome test and the 
Rivermead behavioural memory test, was associated with worsening QoL. In a 
longitudinal study, Fujii et al. (2004) reported that WM (measured using the digit 
span task) predicted QoL (measured using the brief QoL inventory (BQOLI). 
Flensner et al. (2013) reported that perceived problems with memory, attention and 
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concentration, measured by the Perceived Deficit Questionnaire (PDQ) and fatigue 
measured by the Fatigue Severity Scale (FSS) were contributing factors in the health-
related quality of life (HQOL) domain of bodily pain and vitality. However, other 
studies have not found any significant correlation between cognition in MS and QoL. 
A weak point in most studies demonstrating such a relationship seems to be that they 
have not taken clinical variables such as disease duration and disability (EDSS) into 
account or corrected for these factors. In a study of 120 MS patients and 44 healthy 
controls that controlled for EDSS score, fatigue, cognition, mood disorder, 
personality and presence of behavior disorders, Benedict et al. (2005) found no 
significant relationship between cognitive function and health-related QoL (HQOL). 
However Benedict et al. found that vocational status was predicted by cognitive 
function as well as disease duration and conscientiousness. Similarly, in a study of 
359 MS patients, Van Schependom et al. (2014) noted an absence of significant 
relationship between performance in a task measuring WM and IPS (PASAT) and 
HQOL, when EDSS score, disease duration and onset type were into account. 
However, they did find a significant relationship between walking distance (EDSS) 
and manual control (measured by the 9-hole peg test) and HQOL. A fundamental 
problem in these studies is that self-reporting of HQOL by the MS patients could be 
biased because of their cognitive impairment.           
 
2 AIMS OF THE THESIS 
The overall aim of the thesis was to explore and describe various aspects of cognition 
in MS, particularly in relation to long-term MRI findings and plasma concentrations 
of cerebrosterol. 
The specific aims of the studies were: 
I: to investigate how different aspects of cognitive function change over an 8-year 
period in a cohort of MS patients and in subgroups within this cohort, and to relate 
these changes to demographic (age, gender, and education) and clinical (age at onset, 
disease duration, and disability measured by EDSS) characteristics at baseline and 
follow-up. 
II: to investigate lexical substitution and retrieval in MS patients in comparison with a 
matched control group of healthy individuals. 
III: to investigate the associations between cognitive, sensory and motor IPSs as well 
as verbal dichotic listening (VDL), and the area of the corpus callosum in MS patients 
at baseline and at follow-up approximately 9 years later. 
IV: to investigate the relationship between IPS (measured by SDMT) and cholesterol 
degradation (expressed as plasma levels of cerebrosterol), taking into account 
normalized MRI estimates of RBV, volumes of grey and white matter, and ventricular 
CSF volume, and disability (EDSS) in a cross-sectional sample of MS patients. 
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3 MATERIALS AND METHODS 
3.1 Subjects 
Study I, an eight-year longitudinal study, included 31evaluable subjects from a cohort 
of 32 MS patients (21 females) seen consecutively at the outpatient ward of the 
Department of Neurology, Karolinska University Hospital Huddinge, Sweden, during 
June to December 1995. The patients had clinically definite MS according to the 
Poser criteria (Poser et al. 1983). At follow-up about 8 years after the baseline 
measurements, in 2003, 1 male individual in the sample died. The patients were 
classified according to the Lublin classification as RR-MS (n=10), SP-MS (n=17), 
and PP-MS (n=4) at baseline in 1995. At follow-up in 2003, a switch from RR-MS to 
SP-MS had occurred in 5 patients. At baseline, the mean age of all included subjects 
was 42.9 years (SD=10.1y), the mean duration of disease was 12.1 years (SD=9.1y), 
and the mean EDSS score was 4.1 (SD=2.3). The EDSS score at follow-up was 5.5 
(SD=2.2). 
There were more women than men in the evaluable patient group (21/10), which 
approximately mirrors the distribution of the genders in the total MS patient 
population. The evaluable patients had a mean disease duration of about one decade 
at baseline. There were no significant differences in gender distribution or disease 
duration between subgroups at baseline, according to one-way ANOVA testing. 
Patients in the SP-MS and PP-MS groups were on average middle-aged on admission. 
The RR-MS patients were significantly younger and less well educated than the SP-
MS and PP-MS patients, while the latter groups had similar mean ages and levels of 
education. Physical disability (EDSS) was relatively severe in the SP-MS and PP-MS 
patients and did not differ between these groups, whereas it was relatively mild in 
patients with RR-MS (Table 1). 
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Table 1. Demographic and clinical characteristics (Age at disease onset, Duration of 
disease and Disability according to EDSS) in a cohort diagnosed 1995 with Multiple 
Sclerosis.  
  
 Subgroups  
   
 Relapsing Secondary Primary All 
 Remitting Progressive Progressive subjects* 
  
N (females/males) 10(4/6) 17(14/3) 4(3/1) 31 (21/10) 
Age, y 36.5±8.9 45.8±10.0 46.3±7.2 42.9±10.1 
Age at disease onset, y 28.0±8.9 31.6±8.1 33.8±7.0 30.7±8.2 
Education, y 9.9±1.5 12.7±2.5 12.7±0.6 11.9±2.4 
Duration, y 8.5±8.3 14.2±8.8 12.6±12.0 12.1±9.1 
EDSS 2.2±1.9 4.6±2.0 5.8±2.1 4.1±2.3 
  
*1 deceased male patient excluded 
 
Study II, which was a cross-sectional study carried out during 2004-2005, included 
25 evaluable patients who had participated in study I, and 25 healthy controls. The 
remaining six patients from study I were not evaluable for study II: four did not want 
to participate, one had moved abroad, and one was prevented from participating for 
other reasons. The patient group included 16 women and 9 men (RR-MS: n=7, SP-
MS: n=15, PP-MS: n=3) with a mean age of 44.4 years (SD=10.1y) and the control 
group included 17 women and 8 men with a mean age of 41 years (SD=16.0y). The 
mean duration of disease in the MS group was 20 years (SD=9.4y) and the mean 
EDSS score was 5.8 (SD=2.1). The mean duration of formal education was 11.8 years 
(SD=2.4y) in the MS group and 13.0 years (SD=2.8y) in the control group. The 25 
healthy controls were not significantly different in mean age, mean duration of formal 
education, and estimated full-scale intelligence quotient (FSIQ) from the patients with 
MS.  
Study III was carried out in 22 MS patients (16 females and 6 males) who had all 
participated in study I. The patients were neuropsychologically tested and 
investigated by MRI at baseline in 1995 and at follow-up about nine years later, in 
2004-2005. This study was run partly in parallel with studies II and IV, and all of the 
evaluable patients also took part in studies I and II. The remaining nine patients of the 
original 31 from study I did not participate in study III because: four patients did not 
want to participate, one had moved abroad, one was unable to undertake MRI because 
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of an intracranial surgical clip, and three PP-MS patients were excluded because of 
their small number. At baseline there were eight RR-MS patients and 14 SP-MS 
patients. Three patients had changed from RR-MS to SP-MS at follow-up. The mean 
age at baseline was 42.7 years (SD=10.9y), the mean duration of education was 11.7 
years (SD=2.6y), the mean age at disease onset was 29.4 years (SD=8.3y), and the 
mean disease duration was 13.3 years (SD=9.1y). The EDSS disability score was 4.0 
(SD=2.0) at baseline and 5.5 (SD=2.2) at follow-up.    
Study IV was a cross-sectional study carried out during 2004-2005, partly in parallel 
with studies II and III. All the patients (14 females and 7 males) in study IV were part 
of the original cohort from study I. Among the individuals in study IV, 1 had only 
participated in study I, 3 had participated in study I and II and 17 in study I, II and III. 
The MS subgroups consisted of 7 RR-MS patients, 11 SP-MS patients, and 3 PP-MS 
patients. The mean age at examination was 48.3 years (SD=9.5y), the mean duration 
of education was 11.6 years (SD=2.2y), the mean age at disease onset was 29.9 years 
(SD=8.3y), the mean disease duration was 18.5 years (SD=9.0y), and the mean EDSS 
score was 5.5 (SD=2.4).  
The demographic and clinical characteristics of patients in studies I-IV are 
summarized in table 2, and a graphic overview of participation in the studies is 
presented in Fig 1.  
 
Table 2. Demographic and clinical characteristics for the study samples in study I-IV    
  
Characteristic Study I Study II Study III Study IV  
 baseline cross-sectional baseline cross-sectional  
 1995 2004-2005 2004-2005 2003-2004 
  
N (females/males)  31 (21/10 25(16/9)  21 (16/6)  21(14/7)  
Age, y 42.9±10.1 44.4±10.1 42.7±10.9  48.3±9.5 
Age at onset, y 30.7±8.2  24.4± 29.4±8.3  29.9±8.3 
Education, y 11.9±2.4 11.9±2.4 11.7±2.6 11.6±2.2 
Duration, y 12.1±9.1 20.0±9.4 13.3±9.1 18.5±9.0  
EDSS 4.1±2.3 5.8±2.1 4.0±2.0 5.5±2.4  
EDSS at follow-up 5.5±2.2   5.5±2.2 
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In study I, neuropsychological assessment of cognitive function, using a battery of 15 
evidence-based neuropsychological tests chosen to cover different aspects of 
information processing, memory, language function, various executive functions, 
spatial function, and motor function, was carried out at baseline in 1995 and at 
follow-up in 2003. The following neuropsychological tests were used: 
1. The Swedish version of the vocabulary test (half-scale) from the revised Wechsler 
adult intelligence scale (WAIS-R), to measure verbal ability (Wechsler 1981; Bartfai 
et al. 1994). 
2. The similarities test from the WAIS-R, to measure verbal abstraction (Wechsler 
1981; Bartfai et al. 1994). 
3. The COWAT, to measure word fluency (using the letters FAS) (Lezak 1995). 
4. The Rey-Osterieth complex figure (RO) copy test, to assess visuospatial ability by 
copying a complex figure (Lezak 1995). 
5. The picture arrangement test, to assess visual-based comprehension, from the 
WAIS-R (Wechsler 1981; Bartfai et al. 1994). 
6. The digit span test from the WAIS-R, to measure verbal short-term memory and 
WM (Wechsler 1981; Bartfai et al. 1994). 
7. The Corsi block-tapping span test, to measure visuo-spatial short-term memory 
(Lezak 1995). 
8. The RAVLT, to assess verbal episodic memory according to total learning and 
retention (Lezak 1995). 
9. The Rey-Osterrieth retention test, to measure visuo-spatial episodic memory 
(Lezak 1995). 
10. The SDMT test (oral form), to measure IPS (Lezak 1995). 
11. The visual reaction time (VRT) and auditory reaction time (ART) from the 
automated psychological test system (Levander and Elithorn 1987). 
12. The finger-tapping  (FT) test, to assess motor speed in the right and left hands 
(Lezak 1995). 
The administration of this test battery was completed in about 90 min. 
 
In study II, the pre-morbid FSIQs for the MS patients and controls were estimated 
using the Swedish lexical decision test (SLDT) (Almkvist et al. 2007). Current global 
cognitive functioning was assessed for each patient using a summary test (equivalent 
to the FSIQ) based on the following tests: vocabulary (WAIS-R), similarities (WAIS-
R), digit span (WAIS-R), block design (WAIS-R) and SDMT score transformed to 
the corresponding digit symbol score in the WAIS-R test. The FSIQ was calculated 
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using the following linear addition process to give the estimated current FSIQ, from 
the WAIS-R manual (Bartfai et al 1994): 2 x the weighted scores on the verbal tests 
plus 1.5 x the weighted scores on the performance tests. It was not necessary to assess 
the controls for anything other than FSIQ (using the SLDT), since premorbid and 
current intelligence are highly correlated in healthy persons.  
The lexical ability of the MS and control groups was tested using the following tests: 
1. The Boston Naming test (BNT) a confrontation picture-naming test (Kaplan et al. 
1983). The following measures were calculated in the BNT: the number of correct 
responses and omitted responses, the semantic specificity, and the number of off-
target associative responses (visual, semantic, contextual and phonemic). 
2. The COWAT (FAS) for measuring word fluency (Lezak 1995). This included 
analysis of the cluster size and the number of switches between clusters, according to 
a scoring procedure developed by Troyer et al. (1997). In this context, clusters were 
defined as groups of successively produced words beginning with the same two first 
letters, words that differed by one single vowel sound, rhymes, and homonyms. 
 
In study III, IPS (cognitive, sensory and motor) was measured at baseline in 1995 and 
at follow-up in 2004-2005 using the following tests: 
1. The SDMT (oral form) (Lezak 1995) for measuring IPS with a cognitive 
component. 
2.The VRT and ART tests from the automated psychological test system for 
measuring sensory speed (Levander and Elithorn 1987). 
3. The FT test for measuring motor speed in the right and left hands (Lezak 1995). 
At follow-up, auditory inter-hemispheric transfer was assessed using the Verbal 
Dichotic Listening (VDL) (Hugdahl 1988).  
 
In study IV, IPS was assessed using the SDMT according to the standard oral 
procedure (Lezak 1995).  
 
3.2.3 Magnetic resonance imaging and analysis 
The MRI imaging in studies III and IV was performed at the Karolinska University 
Hospital. 
In study III, the MRI examinations were performed at baseline in 1995 by Leszek 
Stawiarz and again at follow-up in 2004-2005 by Leszek Stawiarz, Juha Martola and 
Maria Kristoffersen Wiberg, using a 1.5T scanner and a standard head coil. At 
baseline, a fast spin echo technique was used for image acquisition. Sagittal T2-
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weighted continuous 5-mm imaging sections were obtained. A turbo spin echo 
technique was used at follow-up and sagittal T2-weighted 4 mm imaging sections 
were obtained. The T2 lesion load at baseline and follow-up was defined as the total 
number of T2-weighted lesions. A two dimensional analysis of corpus callosum area 
CCA was carried out using the Sectra PACS system (Linköping, Sweden). In this 
procedure, the CCA was measured three times and the mean of these measurements 
was calculated. The volumes of the lateral ventricles, the third ventricle and the brain 
parenchymal tissue expressed as the RBV (brain volume divided with intracranial 
volume) were evaluated on the original T1-weighted images, using a volumetric 
method and the semi-automated tool in the Hermes MultiModality - region growing 
program. The procedures for MR imaging, evaluation of CCA, and volumetric 
measurement are described in Martola et al. (2007). 
In study IV, the MRI examinations were performed in 2004-2005; the results were 
evaluated by Leszek Stawiarz, using a 1.5T scanner (Magnetom, Siemens, Erlangen, 
Germany) with a standard head coil. The MRI protocol was an extended clinical 
protocol including T1-weighted pulse sequences (MPRAGE) with 1.5 mm axial 
slices, TR=13.5, TE=7, TI=300 ms, field of view=25 cm, and matrix=256x256. 
Images from this sequence were also used for the volumetric analysis.  The FSL 
software package v. 4.1 (FMRIB Analysis Group, Center for Functional Magnetic 
Resonance Imaging of the Brain, Oxford) (Smith et al. 2004) was used to evaluate the 
volumes of brain tissue. The fully automated SIENAX (Structural Image Evaluation, 
Using Normalization of Atrophy) method was used to estimate normalized brain 
volumes from a single image. The brain volume, ventricular space volume, and 
volumes of grey matter and white matter were obtained and normalized for skull size 
(normalization to MNI152 standardized stereotaxic brain template) (Jenkinson et al. 
2001). The brain volume was measured as the RBV proportion in relation to 
intracranial volume, while the others were measured in cm3. 
 
3.2.4 Biochemical analysis  
In study IV, Virginija Danylaite Karrenbauer was responsible for the blood sampling 
logistics in 2004-2005. Biochemical analysis of cerebrosterol concentrations in 
plasma was carried out at the Department of Clinical Biochemistry at Karolinska 
University Hospital, Huddinge. After taking the blood sample, the plasma was 
separated by centrifugation and frozen for storage. Isotope-dilution mass 
spectrometry was then carried out according to the procedure described by Dzeletovic 
et al. (1995) to determine the concentrations of cerebrosterol in the plasma.  
 
3.2.5 Statistical analyses 
The statistical software packages used were the IBM SPSS version 14, USA, in 
studies I and II, and the IBM SPSS Statistics version 19, USA, in studies III and IV.  
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3.2.5.1 Study I  
The demographic and cognitive characteristics of the total sample of patients with MS 
and the subgroups (RR-MS, SP-MS and PP-MS) were described using means ± 
standard deviation (SD). Z-scores were used to compare the results of the various 
neuropsychological tests. These test results were computed on the basis of reference 
values from test manuals and handbooks. Two-way analysis of variance (ANOVA) 
was used for the subgroups between factors and the times of assessment, at baseline 
in 1995 and at follow-up in 2003, and within factors for each neuropsychological test. 
Two-way analysis of covariance (2 subgroups x 2 times; ANCOVA) was used for 
each neuropsychological measure in order to see whether there was cognitive decline 
over time, for differences between subgroups, and to analyze the influence of age, 
gender, education and EDSS scores. At this initial subgroup analysis, the PP-MS 
group was excluded because of its small size. The subgroups were also compared by 
multivariate analysis of variance. The influence of single demographic and clinical 
disease variables was analyzed by means of two-way ANOVA on each cognitive 
variable, using a median split of the background variables (age, gender, education, 
age at onset, disease duration, and EDSS score at baseline and follow-up). A 
Bonferroni correction was done for the associations found between various 
neuropsychological measures and clinical variables in order to control the familywise 
error rate, i.e. the probability of false significant results (type I errors), which can 
occur when making multiple comparisons. 
3.2.5.2 Study II 
Means and standard deviations were calculated for the various test results. One-way 
ANOVA was used to compare the MS group with the healthy control group with 
respect to demographic variables (age and education) and language variables. 
Pearson’s correlation coefficients were used to calculate the correlations between 
lexical variables and between demographics and lexical variables. A Bonferroni 
correction was applied to these correlation analyses. 
3.2.5.3 Study III 
Separate stepwise regression analyses were performed for each neuropsychological 
test at baseline and follow-up as well as for the annual rate of change (ARC) in CCA 
in each neuropsychological test, to evaluate the effect of CCA on information 
processing. Demographics (age at baseline, gender, years of education), clinical 
characteristics (onset of symptoms, duration of disease and severity of disease as 
assessed by EDSS), as well as MRI measures (RBV and T2 lesion load), were 
included as possible predictors in order to adjust for possible confounding factors. 
Because of the small sample size, it was not appropriate to test for interactions among 
the explanatory variables. 
3.2.5.4 Study IV 
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When presenting data (demographics, SDMT scores, brain measurements, EDSS 
scores, and cerebrosterol levels), descriptive statistics (means±SD) were used. The 
relationships between SDMT, EDSS, demographics (age, gender and education), 
volumetric MRI, and cerebrosterol results were calculated using Pearson correlation 
coefficients. Two types of stepwise multiple regression analyses were performed 
using a backward elimination procedure. The dependent variable in one of the 
stepwise regression analyses was the SDMT raw score and in the other the EDSS 
score. In both stepwise regression analyses, MRI normalized measures of brain 
volume, grey and white matter and ventricular CSF volumes, cerebrosterol levels and 
demographics were added as possible predictors of SDMT and EDSS. 
 
3.3 Ethical considerations 
Ethical approval for study I was obtained from the Local Research Committee at 
Huddinge Hospital (21/95); the Research Ethics Committee KI, South (Dnr 55/03); 
and the regional Ethics Committee in Stockholm (04-906/4). An ethical application 
for study II was added to the ethical application for study I and was approved (Dnr 
55/03). The Regional Ethics Committee, Division 4, gave ethical approval for study 
III (Dnr 04-906/4). Ethical approval for study IV was received from the Research 
Ethics Committee KI, South (Dnr 322/02), and the Regional Ethics Committee, KI 
(Dnr 02-548). 
The participants were clearly informed about the procedures and aims of the study 
before participation. The information given to the participants was in neutral written 
form which allowed easy refusal to participate without having to explain reasons. All 
data concerning participants were treated in a safe, anonymous manner. 
 
4 RESULTS 
4.1 Study I 
At baseline, the whole MS patient group already had poor results (cut-off at –1.5 SD) 
on the ISP tests symbol digit, VRT and ART (table 3). At this stage, when the 
average disease duration was about 12 years, there were no significant differences in 
mean test performance results between the subgroups (RR-MS, SP-MS and PP-MS) 
except for in the Corsi span test. The disease duration at baseline was associated with 
impaired performance in the RO copy test, the symbol digit test, the VRT test, and 
the FT test for the dominant and non-dominant hands. 
The greatest decline over the eight years' follow-up in the total MS group was seen in 
the VRT results, followed by the RO Copy, the FT right hand and the Corsi span test 
results (table 3). The cognitive deficits in the total group at baseline and follow-up 
were most pronounced in the three ISP tests (symbol digit, VRT and ART) while 
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there was no significant decline in either the verbal ability test or the learning and 
memory tests during the follow-up period. 
There was a differential pattern of cognitive decline over time in the subgroups of the 
MS patients. Thus, the SP-MS group had a marked decline in VRT, while the scores 
for this test did not decline significantly in the RR-MS and PP-MS groups  MS 
patients with optic neuritis did not perform any worse than those without optic 
neuritis in the VRT test. In contrast, none of the MS subgroups showed any 
significant decline over time in the ART test  Nor was there any significant decline 
over time in any of the subgroups nor any group differences in the vocabulary test 
and the other non-speeded tests. 
The results revealed that old age had a negative influence on most of the 
neuropsychological test results. In contrast, there were no obvious  interactions 
between gender and a decline in cognition. There was also no such interaction for 
education overall, except for a significant effect on vocabulary. There was no 
interaction between a decline in cognitive functioning and gender, age at onset of 
disease, or disease duration. The results suggested an absence of any evident 
relationship between disability and cognitive functioning at baseline. In contrast, a 
high EDSS score (>6) at follow-up had a significantly negative effect on performance 
in tests measuring motor speed, visual IPS, verbal learning and retention.  
Initial impairment predicted further cognitive decline. Tests measuring IPS were 
especially strongly connected with decline over time.  
In summary, the results for the total MS group showed an initial selective pattern with 
a marked decline in the IPS tasks already at baseline and a pronounced decline over 
time, especially in visual IPS, while there was no significant time-related 
deterioration in auditory IPS. Initial marked cognitive deficits, especially in IPS tests, 
predicted further cognitive decline. In the subgroups, there was a differential pattern 
over time, with the most pronounced cognitive deterioration occurring in the SP-MS 
group, which showed a marked deterioration in visual IPS compared to auditory IPS. 
High EDSS scores at follow-up were related to cognitive decline. 
 
4.2 Study II 
The control group had a significantly higher number of correct responses, including 
target responses, subordinated responses and synonyms, in the BNT than the MS 
patients and had significantly fewer omitted responses (table 4). 
The MS patients' responses in the BNT were less specific and contained more inexact 
and more superordinated descriptions as substitutions for correct target responses 
(table 4). The MS group also made significantly more semantically off-target 
associations than the controls in the BNT. 
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On the word fluency COWAT (FAS), the MS patients generated significantly fewer 
correct words and switched significantly fewer times between clusters than the 
controls. However, there were no differences concerning the cluster size (table 5). 
For all participants, there was a significant positive correlation (Pearson correlation 
coefficient) between the BNT variables (number of correct responses) and the current 
FSIQ, and a negative correlation between the number of nonspecific responses and 
the FSIQ. Furthermore, there was a significant positive correlation between the 
COWAT variables (number of correct words, cluster size and cluster switches) and 
the current FSIQ. However, there was no significant correlation between the BNT and 
the COWAT with relation to demographic variables (age and education). 
There was a correlation between substitutive responses and retrieval strategies. Thus, 
a low number of correct responses on the BNT was significantly correlated with a 
high occurrence of nonspecific responses and off-target associations. There was also a 
significant correlation between the number of correct responses on the BNT and the 
COWAT results. A significant correlation was seen between correct responses on the 
BNT and frequent switches between clusters on the COWAT. However, no 
correlation was found between correct responses on the BNT and a high cluster size 
on the COWAT. A high total number of correct words on the COWAT correlated 
with a low occurrence of nonspecific responses and with a low frequency of off-target 
associations on the BNT, and frequent switches on the COWAT was correlated with a 
low proportion of nonspecific responses on the BNT. 
In summary, the MS group had fewer correct responses and more omitted responses 
on the BNT than the control group. Furthermore, the MS patients gave less-specific 
descriptions as substitutions for the target word. Also, the MS patients had fewer 
words on the COWAT and fewer switches between clusters than the controls. Good 
performances in the BNT and COWAT were correlated with a high current FSIQ in 
both the MS and control groups. There was also a correlation between the 
performances on the COWAT and the BNT. 
 
4.3 Study III 
The RR-MS and SP-MS subgroups did not differ regarding demographic 
characteristics (age, gender, and education) but the SP-MS group had a significantly 
higher EDSS score at baseline and follow-up. The SP-MS group also had a 
significantly smaller CCA at baseline and at follow-up. However, the rate of corpus 
callosum atrophy did not differ between the groups. The RBV was significantly 
smaller in the SP-MS group than in the other groups at baseline, but not at follow-up. 
There were no differences between groups regarding the ARC in the RBV, the T2 
lesion load at baseline or at follow-up, or the ARC in the T2 lesion load. 
A significant difference between the groups in favor of the RR-MS group appeared in 
the SDMT performance at both baseline and follow-up, and in the VRT and FT 
(dominant and non-dominant hands) tests at follow-up.  
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In the whole group at baseline (1995), a small CCA was associated with a poor 
performance on the SDMT and a long disease duration and high T2 lesion load were 
associated with a poor performance on the FT test for both hands (fig. 3). 
At follow-up (2004-2005), a small CCA was also related to poor performance on the 
SDMT (fig. 4). Furthermore, an association between a high EDSS score and a poor 
FT speed for both hands was seen at follow-up. At the same time-point, a small RBV 
was associated with a good performance in the right ear in the VDL test (VDLr), 
while a small CCA was associated with a poor left ear performance on the VDL test 
(VDLl). 
There was no significant association between performance in the SDMT and the ARC 
for any other variable. However, the VRT was significantly associated with the ARC 
in the CCA. A significant association between the ART and the ARC in the RBV and 
disease duration was also seen. 
VDLr performance was significantly positively associated with the ARC in the RBV. 
However there was no significant association between VDLr performance and the 
ARC in the CCA or the ARC in the T2 lesion load. On the other hand, the VDLl 
performance was significantly negatively associated with the ARC in the CCA. The 
higher the ARC in CCA, the lower percentage of correct responses were registered on 
the left ear and the higher percentage of correct responses on the right ear. 
In summary, the main result was that the CCA, in contrast to the RBV and the T2 
lesion load, was positively correlated with performance in the SDMT, both at baseline 
and at follow-up. 
 
4.4 Study IV  
The MS patients in study 4 had moderate physical disability according to the EDSS 
score and a clearly lower mean performance on the SDMT than healthy adults (Lezak 
1995). The mean grey matter volume was slightly smaller than normal values in the 
whole sample (Lüders et al. 2002). Furthermore, the mean levels of plasma 
cerebrosterol in the sample were higher than in healthy people (Dzeletovic et al. 
1995). ). 
A poor performance in the SDMT was significantly correlated with a small grey 
matter volume, a small brain volume, a large ventricular volume and high levels of 
cerebrosterol. However, there were no significant correlations between the SDMT 
and either white matter volume or duration of education. A strong correlation was 
seen between a high EDSS score and high levels of plasma cerebrosterol. In contrast, 
there were only weak correlations between the EDSS scores and a small brain volume 
or large ventricular volume (table 6). 
Age was significantly negatively correlated with brain volume  and significantly 
positively correlated with ventricular volume. The duration of education was 
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significantly positively correlated with the volume of grey matter and significantly 
negatively correlated with the volume of white matter. A significant correlation was 
seen between high levels of plasma cerebrosterol and a large ventricular volume. 
However, there was no significant correlation between high levels of plasma 
cerebrosterol and the MRI volumetric measures. 
A stepwise multiple regression analysis was done, using backward elimination of 
possible predictors, MRI volumetric measures, and concentrations of cerebrosterol, in 
order to find predictors related to SDMT performance. This analysis showed that 
brain volume, grey matter volume and plasma levels of cerebrosterol were 
significantly and independently related to performance in the SDMT. When age, 
gender and education were added to the MRI measures and the plasma levels of 
cerebrosterol as possible predictors of SDMT, the prediction gained no further power. 
There were no obvious differences between the groups (RR-MS, SP-MS and PP-MS) 
concerning the relationships between possible predictors and the SDMT performance.  
In order to investigate whether each predictor (grey matter volume, brain volume and 
cerebrosterol level) had a true independent effect on SDMT performance or whether 
these predictors interacted, a number of stepwise analyses were carried out. 
Interaction variables were added and all possible pairwise combinations of predictors 
were analyzed with respect to their shared variance. For all three combinations of 
predictors (grey matter volume and cerebrosterol, grey matter volume and brain 
volume, and brain volume and cerebrosterol), the shared variance for the predictors 
was relatively small. 
A stepwise regression analysis was also performed with EDSS as the dependent 
variable and the MRI volumetric measures (brain volume, the volumes of grey and 
white matter and the ventricles) and plasma levels of cerebrosterol as independent 
variables. This analysis showed that high EDSS scores were significantly related to 
high plasma levels of cerebrosterol. Adding age at onset of disease as a predictor 
clearly improved this relationship.  
In summary, a poor performance on the SDMT was associated with a low volume of 
grey matter and high levels of cerebrosterol, while a high EDSS score was associated 
with high levels of cerebrosterol. 
 
5 DISCUSSION 
5.1 The focus of this thesis 
This thesis investigates cognitive functioning in patients with MS, with a special 
focus on long-term MRI findings and plasma cerebrosterol levels.  
5.2 Study I 
In study I, the first finding was that even at baseline, there was selective decline in 
visual IPS tasks, with impaired VRT but not ART, in the whole MS group. Previous 
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studies confirm that IPS is the most frequently impaired cognitive domain early in the 
MS course (Nocentini et al. 2006). Impaired IPS can even occur in the CIS (Khalil et 
al. 2001). However, the selective pattern, with a more marked decline in visual IPS 
than in auditory IPS, is new. Since patients with optic neuritis in study I, did not 
perform worse in VRT, than those without optic neuritis, it could be assumed that 
impaired VRT does not depend on optic nerve dysfunction. It is possible that the 
more pronounced decline in visual IPS is partly because the optic tract has a larger 
extension in space than the auditory neural network and therefore could be more 
vulnerable to MS lesions. The anterior loop of the optic radiation (Meyer´s loop) 
travels around the inferior horn of the lateral ventricles and at the middle aspect of the 
temporal horn, the optic radiation is located at the roof and lateral wall of the lateral 
ventricles (Eberling and Reulen 1988). MS lesions indicating demyelination 
frequently have a bilateral periventricular distribution, especially in the tract of the 
lateral angles of the lateral ventricles (Allen 1991) and therefore the anterior loop of 
the optic radiation is putatively exposed for those lesions, which could contribute to 
the decline in information processing.  
In contrast to this prominent impairment in IPS, performance in the verbal tests was 
not affected. Putatively, the functions measured by different tests may have different 
thresholds with regard to the amount of cerebral dysfunction required before visible 
impairment appears. Possibly compensatory brain mechanisms are backing up the 
diverse cognitive functions in different degree, thereby making them variously 
resistant to brain pathology. The differences could also be the result of MS affecting 
different brain regions at different times during the disease course, and the tests 
measuring functions in different locations in the CNS. It is possible that the type of 
MS course is important for the time at which and the degree to which specific regions 
in the CNS are affected, and the time at which cerebral dysfunction is measurable by 
a specific test.           
The second finding in study I was that incipient cognitive decline, especially in IPS, 
predicts further cognitive decline over time in the MS patients, which agrees with 
previous findings (Amato et al. 2010). This could be due to underlying progressive 
neurodegenerative brain pathology. There is evidence of early grey matter atrophy in 
the CIS and the initial stages of RR-MS (Dalton et al. 2004). Morgen et al. (2006) 
found cortical atrophy in early RR-MS which correlated with impairments in IPS and 
EFs measured by the PASAT. In contrast, cognitive functions that were well 
preserved at baseline tended to be better preserved at follow-up eight years later. The 
finding in study I that deterioration over time is especially marked in IPS is supported 
by other reports (Denney et al. 2008). The markedly pronounced decline in 
information processing could putatively due to that it is an unspecific and global 
function, being affected by brain pathology independently of it´s location. 
The third finding in study I was the differential pattern of cognitive decline over time 
in the subgroups, with the most marked decline in the SP-MS group, particularly in 
relation to the RR-MS group and most apparent in visual information processing 
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speed as compared to auditory information processing, after correction for group 
differences concerning age, education and EDSS score. The more marked cognitive 
decline in the SP-MS group than the RR-MS group and PP-MS group is consistent 
with earlier reports. Beatty et al. (1989) found that SP-MS patients were more 
severely impaired than RR-MS patients, and Denney et al. (2005) reported that an SP-
MS group had greater cognitive deterioration than a PP-MS group. It has been 
demonstrated that grey matter atrophy accelerates when RR-MS switches to SP-MS 
(Fisher et al. 2008), which could have contributed to the more severe cognitive 
decline in the SP-MS group. Possibly, the remissions in the RR-MS group slow down 
the disease progress thereby sparing it from cognitive decline to a higher degree than 
the SP-MS and PP-MS group. The small sample size in the subgroups calls for 
caution in the interpretation of the results, however. 
The fourth main finding was the association between a high EDSS score (>6) and 
selective cognitive decline, primarily in IPS, at follow-up but not at baseline, for the 
whole MS group, is consistent with some reports of a relationship between cognitive 
functioning and EDSS (Lynch et al. 2005).  However studies of the relationship 
between cognitive status and EDSS have yielded disparate results and some have not 
found any significant relationship of that sort (Amato et al. 2010). In contrast to an 
interaction in study I, between a high degree of disability at follow-up and high age in 
relation to cognitive decline, neither gender, age at onset nor disease duration had any 
effect on cognition. It is also notable that education had no effect on cognitive 
performance except vocabulary. It is possible that the association occurred because 
many of the MS patients had switched to an SP-MS course during follow-up, possibly 
with an associated higher degree of neurodegeneration and more pronounced physical 
disability; the older age of the participants could also have been a factor.                   
In conclusion, the notation in study I of an early selective cognitive decline in MS, 
primarily in visual information processing in comparison to auditory information 
processing is a new finding. The observation that early cognitive deterioration in MS, 
mainly in information processing speed, predicts further cognitive decline and has no 
association initially with physical disability, suggests an underlying sub-clinical 
disease factor, putatively neurodegeneration, running side by side  with visible 
cognitive decline. The absence of confounding influence by gender, education, age at 
onset and disease duration in speeded information task performance strengthens the 
impression of a possible underlying independent pathological factor(s). In contrast, 
aging and high degree of disability at follow-up effects cognition, particularly 
information processing speed negatively. Putatively the differential pattern in study I, 
with the SP-MS group seeming to have a more pronounced cognitive impairment 
than the other groups, most obvious in visual reaction time compared with  auditory 
reaction time, could to some part due to a that SP-MS patients have a more developed 
neuropathology. However these group differences must be interpreted with special 
caution with respect to the small sample size. 
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5.3 Study II 
Study II differed from studies I, III and IV in that it investigated language function, 
and not primarily IPS. This study showed greater deficits in the MS patients than in 
the control group in the use of strategies for substituting target words and strategies 
for letter-word fluency retrieval, as measured by the BNT and the COWAT (FAS), 
which is consistent with previous findings. Thus the finding in study II that the MS 
patients had a higher frequency of errors in the Boston Naming Test is in accordance 
with a similar finding by Laatu et al. (2001) and the smaller number of words as well 
as more frequent use of dysexecutive strategies in FAS fluency also seen in study II, 
is consistent with the findings by Tröster et al. (1998). Furthermore in study II, the 
poor performance in Boston Naming Test and FAS fluency was corresponding to a 
general drop in the MS patients current FSIQ.  
A limitation of study II was that it did not investigate language function in relation to 
brain MRI measures. While few studies have looked into the relationship between 
language function and neuroradiological findings, Amato (2004) has demonstrated an 
association between poor performance in verbal fluency and grey matter atrophy. 
PET and fMRI studies have shown that word generation tasks as FAS fluency are 
associated with activation of left frontal regions Cabeza and Nyberg (2000). On the 
other hand lexical-semantic retrieval of name associated with a picture in the Boston 
Naming Test has been reported to activate the left middle temporal gyrus and 
underlying white matter (Baldo et al. 2013). Putatively neurodegeneration in MS 
could affect these fronto-temporal areas of importance for word-generation and 
lexical-semantic retrieval directly or indirectly by giving a slow information 
processing. Earlier studies on verbal learning have proposed that information search 
processes do not work effectively in MS patients because of slowed mental activity 
(Faglioni et al. 2000). However the reason for the impaired lexical processing in MS 
patients showed in study II is unclear.  
In contrast to the verbal deficits noted in study II, aspects of verbal ability appeared 
well preserved in study I. There were no deficits in the verbal ability tests involving 
vocabulary, similarities and word fluency at baseline nor any decline at follow-up in 
study I. Studies investigating language in MS patients have generally shown that 
language function is relatively well preserved, although subtle comprehension deficits 
have been reported (Langdon 2011). The paradoxical contrast between the well 
preserved word fluency in study I and the poor performance in word fluency in study 
II is possibly the result of the control group in study II, and the more refined analysis 
of word fluency, including the strategies used, which may have helped to detect 
subtle lexical deficits. It may also be possible that the cut-off level in the reference 
data in the test manual used in study I was too low to accurately calculate the z-scores 
in the word fluency test.  
It may also be possible that the poorer performance in word fluency in MS patients 
compared with controls might have been partly affected by the controls having had 
1.2 years more formal education, despite all efforts to match the groups according to 
their demographic characteristics. This may have positively affected the word fluency 
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test results in the control group, and may also have given this group an advantage in 
the BNT, thereby making the finding of lexical deficits in the MS group less 
representative of total the MS population. However, the difference in mean duration 
of education between the MS patients and the control group was not significant, and it 
is reasonable to assume that the findings in study II reflect real, although subtle, 
language disturbances in the MS patients, which could be expected to influence their 
social self-esteem and QoL in a negative way.  
In conclusion, an interesting angle is the notation that the MS group had poorer 
lexical strategies for substitution and  retrieval  than healthy control persons and that 
there was a correlation between the quality of substitutive responses and the adequacy 
of retrieval strategies. It can be assumed that the poor lexical processing in the MS 
group in study II is associated with slow IPS, especially in the word fluency test since 
time pressure is most pronounced in this task; however, this hypothesis needs to be 
tested in future research.     
 
5.4 Study III 
This study focused on the relationship between atrophy in the corpus callosum and 
performance in a cognitively demanding speed task (SDMT), a sensory speed task 
(VRT and ART) and a motor speed task (FT) over nine years, as well as measuring 
auditory inter-hemispheric transfer at follow-up (VDL). The corpus callosum is a 
white matter commissure which connects the hemispheres, allowing inter-
hemispheric connections between subcortical and cortical neurons. 
In this study, the main finding was that, in contrast to the RBV and the T2 lesion 
load, the CCA was associated exclusively with performance in the SDMT. The 
smaller the CCA was at baseline, the poorer was the performance in the SDMT at 
baseline; and the smaller the CCA was at follow-up, the poorer was the performance 
in the SDMT at follow-up. The RBV and the T2 lesion load were associated with 
performance in sensory-motor tests but not with SDMT performance. Adding MRI 
measures (RBV and T2 lesion load), demographic characteristics (age, gender, and 
education), and clinical characteristics (age at onset, disease duration, severity of 
disease according to EDSS, and MS course), did not alter the strength of the 
relationship between the corpus callosum and performance in the SDMT. This 
suggests a relationship between atrophy in the corpus callosum and a decline in 
cognitive IPS early in the initial stages of MS when clinical disability is not yet 
marked. The finding confirms  the assumption of an underlying sub-clinical 
neurodegenerative factor running side by side with clinically visible cognitive 
deterioration that was made in study I.  
The relationship between the CCA and IPS in cognitive tasks has not been studied to 
any great extent. However, a cross-sectional study by Yaldizli et al. (2014) has 
demonstrated that atrophy of the posterior corpus callosum segment is associated with 
poor performance in the SDMT. In a cross-sectional MRI study, Lin et al. also found 
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an association between a small CCA and deficits in attention and IPS as measured by 
the PASAT. The finding in study III of an association between atrophy of white 
matter in the corpus callosum and cognitive IPS does not align with the report by 
Batista et al. (2012), who found  performance in the SDMT to be associated with the 
grey matter volume but not with the white matter volume. It is possible that IPS 
depends more on the corpus callosum than on other white matter regions because of 
the area’s importance in inter-hemispheric connectivity. This assumption is in 
agreement with the finding in a diffusion tensor imaging study by Roosendaal et al. 
(2009) that impaired IPS as measured by the letter digit substitution test (LDST), was 
associated with abnormal fractional anisotropy in the corpus callosum. Putatively, the 
corpus callosum and the neocortex contribute in different ways to cognitively 
demanding information processing, in the sense that the white matter fibers in the 
corpus callosum may be responsible for inter-hemispheric connectivity and speed, 
whereas the neocortex may serve as an associative component on a higher functional 
level. 
In study III, there was no relationship between a high T2 lesion load and a poor 
SDMT performance. However, T2 lesion load at baseline was associated with 
impairment in FT speed. The absence of a relationship between the T2 lesion load 
and the SDMT performance fits the results of several cross-sectional and longitudinal 
studies, in which atrophy was frequently found to have a stronger association with 
cognitive performance than with the overall T2 lesion load (Rovaris et al. 2006). 
Zivadinov et al. (2001), for example, reported that cognitive deterioration relied 
significantly more on the development of brain atrophy than on the T2 lesion load in 
a longitudinal study of brain atrophy and cognitive disturbance in the early phase of 
RR-MS.  
The stronger influence of atrophy than of lesion load on cognitive performance raises 
the question of whether neurodegeneration (as expressed by atrophy) and 
neuroinflammation (shown as gadolinium-enhanced T2 lesions) represent processes 
that are at least partly independent of each other. This view corresponds to findings in 
the prospective 18-month follow-up study by Sailer et al. (2001), in which no 
correlation was seen between T2 lesion volume and atrophy over the follow-up 
period. Earlier experimental studies have also supported the assumption that atrophy 
can be independent of mechanisms causing demyelination. For example, it has been 
reported that axonal loss could be due to an abnormal glial-axonal interaction and 
could occur with only low-grade inflammation (Bitsh et al. 2000) or could even 
appear in the total absence of demyelination and inflammation (Garbern et al. 2002). 
It is assumed that there is an interplay between inflammation, neurodegeneration and 
the dynamic vulnerability of intact axons (Compston and Coles 2008). 
A differential relationship between the VDL (differing between right and left ear 
performance) and the ARC in the CCA and RBV was seen in the MS patients in 
study III. The higher ARC in the CCA in all MS patients at follow-up was related to 
poorer performance in VDLl, with a more marked advantage in VDLr, in the whole 
MS group. A relationship between a higher ARC in RBV and more correct responses 
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with VDLr was also found. Earlier research has also shown an association between 
callosal atrophy and impaired VDLl in RR-MS patients (Pelletier et al. 2001). 
Putatively, the association between impaired VDLl and callosal atrophy occurs 
because left-ear listening, unlike right-ear listening, is highly dependent on the 
auditory callosal pathway and the left ear is therefore more vulnerable to the 
disconnection of this pathway by atrophy than the right ear. It seems reasonable that 
right-ear listening might appear to be improved in association with callosal atrophy 
because of the resulting elimination of sensory interference from the left ear. It seems 
paradoxical that the CCA in study III at follow-up was more strongly associated with 
the SDMT performance than with VDL, since the latter is dependent on inter-
hemispheric transfer. Putatively, this was because auditory inter-hemispheric transfer 
is backed up by ipsilateral pathways and VDL is therefore less dependent on callosal 
functionality than the SDMT.  
A comparison of the subgroups revealed a differential pattern. The SP-MS group 
performed significantly poorer in the cognitive speed task (SDMT) than the RR-MS 
group, both at baseline and at follow-up. Furthermore, the SP-MS patients performed 
less well than the RR-MS group in the sensory-motor speed-demanding VRT and FT 
tasks at follow-up. This differential pattern of decline in cognitive speed over time in 
the subgroups, with an inferior performance in the SP-MS group in comparison with 
the RR-MS group, is in accordance with previous findings (Comi et al. 1995; De 
Luca et al. 2004). Demographic characteristics did not confound this difference 
between the subgroups. However, the EDSS score was higher in the SP-MS group 
and could therefore have influenced the results in the motor speeded FT task, 
especially at follow-up when it was most marked. The finding that the SP-MS and 
RR-MS patients achieved low results in all tests in relation to reference data and that 
they did not differ with respect to RBV at follow-up or ARC in the CCA suggests that 
both groups were impaired in IPS and had brain atrophy. Since no significant 
differences were seen between the RR-MS and SP-MS groups in the ARC in the 
CCA, it is possible that the smaller CCA in the SP-MS group in this study occurred 
because this latter group tended to have a more advanced disease and a longer disease 
duration than the RR-MS group. 
In conclusion, the main finding that CCA in contrast to RBV and T2 lesion load, was 
exclusively associated with the cognitive speed-demanding task and not with the 
sensory-motor speed tasks, makes it putative that CCA has a particular importance for 
cognitive speed. The small sample size brings an amount of uncertainty into the 
results. A shortcoming in the present study is the lack of differentiation between 
different regions of the CCA. However, the finding that the CCA is mainly associated 
with cognitive speed rather than sensory-motor speed represents a new feature which 
could be further enlightened in future research using a larger sample size. 
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5.5 Study IV 
Study IV widens the focus in study III of the relationship between cognition in MS 
patients and MRI findings by investigating the levels of cerebrosterol, which has been 
proposed as a marker for brain cholesterol turnover in the CNS (Bretillon et al. 2000; 
Björkhem 2006). Brain cholesterol is involved in cell membrane structure and 
function, regulating the membrane proteins (Leoni & Caccia (2011). Cerebrosterol 
has a variety of functions in the CNS. It has an important role in the transport of 
cholesterol between astrocytes and neurons (Leoni & Caccia 2013), is a structural 
component of cellular membranes, and is involved in the formation and regulation of 
synapses and growth of dendrites, and exocytosis (i.e. dumping the content of 
synaptic vesicles in the synaptic cleft) (Leoni & Caccia 2014). Furthermore, low 
concentrations of cerebrosterol protect neuronal cells against oxidative stress 
(Noguchi et al. 2014). Leoni (2004) reported that gadolinium-enhanced T2 lesions 
indicating focal inflammatory activity were associated with increased turnover of 
cholesterol in the brain.     
The main finding in study IV was that a slow IPS in MS patients was associated with 
small grey matter volumes and high levels of plasma cerebrosterol, and that a poor 
clinical status (EDSS) was associated with high levels of cerebrosterol. The findings 
of this study agree with those of previous studies that have investigated the 
relationships between cognition and plasma cerebrosterol levels. Hughes et al. (2012) 
found that participants with high plasma levels of cerebrosterol and high 
24OHC/27OHC ratios were at greater risk of developing cerebrovascular disease and 
impairment longitudinally over 8 years. A correlation between cognitive tests (among 
them the SDMT) and decreased plasma levels of cerebrosterol in patients with 
Huntington´s disease was reported by Leoni & Caccia (2013 and 2014). However, our 
study is the first to investigate the relationships between cognition and plasma 
cerebrosterol levels and between the EDSS score and plasma cerebrosterol levels in 
MS patients.  
The MRI normalized measure of brain volume, volume of grey matter and plasma 
levels of cerebrosterol (24OHC) were found to be independent predictors of SDMT-
performance.  With respect to the absence in our stepwise regression analysis of an 
interaction between 24OHC and the neurodegenerative predictors of SDMT in the 
MS patients, it seems probable that neuronal cell death implying axonal loss could be 
induced by the well-known cytotoxicity of 24OHC, thereby affecting SDMT 
performance independently of neurodegeneration. Thus previous studies have shown 
that cerebrosterol 24OHC has potent cytotoxic properties (Kölsch et al. 1999) and 
induces a programmed neuronal cell death by apoptosis or necroptosis i.e. a form of 
more chaotic cell death expressed as necrosis, depending of the enzyme 
serine/threonine kinase 1 (Yamanaka et al. 2011; Noguschi et al. 2014).     
It is notable that the mean level of plasma cerebrosterol tended to be higher in the MS 
patient group in study IV than in the healthy reference group (Dzeletovic et al. 1995). 
Two patients out of the whole group (n=21) had very high values (>2SD). The other 
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patients had plasma cerebrosterol levels within the range for healthy people. The 
somewhat higher than normal mean plasma cerebrosterol levels in the patients in 
study IV might be partly dependent on the fact that the MS patients were older (mean 
age 48.3±9.5 years) than the healthy volunteers in the reference group (15 males, 
mean age 36.7 years; and 16 females, mean age 38.4 years). Bretillon et al. (2000) 
have shown that plasma cerebrosterol concentrations increase with age. However, 
including age in addition to cerebrosterol did not give further power to the prediction 
of performance in the SDMT.  
Among the neurodegenerative predictors in the model with the SDMT result as a 
dependent variable, grey matter volume appeared to be most strongly related to 
SDMT performance. In contrast, white matter volume did not have enough predictive 
strength to be included in the stepwise regression model. Furthermore, there was no 
significant correlation (Pearson) between SDMT performance and white matter 
volume. This result indicates that grey matter is particularly important for IPS. Some 
previous studies confirm the relationship between SDMT performance and loss of 
grey matter volume (Nocentini et al. 2012; Batista et al. 2012). Riccitelli et al. (2011) 
reported that performance in an IPS-demanding task (PASAT 3) was associated with 
distinct patterns of regionally distributed grey matter loss in the fronto-temporal 
lobes, the left hypothalamus and the thalami. In contrast, other studies have shown an 
association between the SDMT results and white matter atrophy and no association 
between SDMT performance and grey matter atrophy (Sanfilipo et al. 2006). It is 
conceivable that the stronger association between a small grey matter volume and IPS 
seen in study IV could have occurred because most of the MS patients in Sanfilipo's 
study had RR-MS with subsequently less grey matter atrophy than the patients in 
study IV most of whom were diagnosed with SP-MS. 
In a model with functional status on EDSS as the dependent variable and brain 
volume, grey matter, white matter and ventricular volumes as well as plasma levels of 
24OHC as independent variables, high plasma concentration of 24OHC significantly 
predicted EDSS. Putatively the cytotoxicity of 24OHC also affects neurons which the 
EDSS functions depend on, inducing apoptosis or necroptosis. This could possibly 
contribute to an impaired clinical ability. In contrast none of the brain volumetric 
measures provided any power to the prediction of ESSS in the stepwise regression 
model. However EDSS showed significant pairwise correlations (Pearson) with brain 
volume as well as ventricular space. Age at onset added strength to the prediction of 
EDSS. This is in accordance with the finding of increasing disability in old age for 
both sexes (Bove et al. 2013).  
The absence of a correlation between the EDSS score and the MRI volumetric 
measures contrasts with the relationship between the SDMT performance and the 
MRI measures, primarily grey matter volume. An absence of correlation between 
grey matter volumes and the EDSS performance was also reported in a study of RR-
MS patients by Chard et al. (2002). In another study of RR-MS patients, Morgen et 
al. (2006) found a correlation between grey matter volume and performance in the 
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PASAT (processing speed and working memory) but no correlation between grey 
matter volume and the EDSS score.  
The difference between the EDSS and the SDMT concerning the presence of a 
relationship with grey matter volume may be due to the latter involving more 
cognitively demanding tasks and therefore depending more exclusively on activity in 
higher associative cortical areas. Forn et al. (2011) showed in an fMRI study of 
healthy participants that IPS measured using the SDMT mainly activates a wide 
frontoparietal network in the cortex. Disability measured using the EDSS, on the 
other hand, can be affected by pathology in many different locations in the CNS in 
addition to the cortex, as well as in non-CNS locations (Chard & Miller 2009). Thus, 
the EDSS quantifies disability in eight functional systems (pyramidal, cerebellar, 
brainstem, sensory, bowel and bladder, visual, cerebral, and “other”). Putatively, 
these functions in the EDSS have different thresholds with respect to how far the grey 
matter pathology has developed before an impairment is obvious, and neuroplasticity 
could possibly make these resistant to atrophy to varying degrees. Thus, the variety of 
functions in the EDSS possibly lessens its association with grey matter volume and 
makes it less specific in comparison with the SDMT. 
In conclusion, the results of study IV suggest that information processing speed in 
MS is affected by neurodegeneration, primarily loss of grey matter volume and levels 
of plasma cerebrosterol a marker of membrane turnover and that these predictors are 
independent. A correlation between the EDSS performance and plasma cerebrosterol 
levels indicates that the latter could be a putative biomarker for MS disease 
progression. However, the small number of MS patients may make the results 
uncertain. In future research, it would be desirable to validate these results by using a 
larger sample size, preferably with a follow-up design. A future study could also be 
enriched by including the aspect of health related quality of life, and vocational status 
in relation to information processing speed, MRI findings and cerebrosterol. 
 
5.6 Methodological limitations and strengths 
5.7 Sample selection and representativeness 
The total number of MS patients in the original cohort in 1995 was relatively small 
(n=32) but only one patient had dropped out from study I at follow-up eight years 
later. The patients in the original cohort were consecutively recruited, which favored 
the representativeness of the samples. However, in studies II-IV, a number of patients 
from the original cohort were missing and the small group size, especially in study 
IV, probably diminished the representativeness of the samples. Also, a small sample 
size implies less power for the test and subsequently an enhanced risk of a type II 
error in interpretation of the results, i.e. that the null hypothesis will not be rejected 
when it is false. In studies I and III, the long follow-up period could, to some extent, 
have compensated for the small sample size.    
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It is also important to take into account the distribution of the subgroups, in the 
context of representativeness. The typical distribution of MS patients is said to be 
RR-MS 45-60%, SP-MS 30-45% and PP-MS 10-15%. In the original sample in 1995, 
from which the MS patients in studies I-IV emanated, the distribution of subgroups 
was RR-MS 32%, SP-MS 55% and PP-MS 13%. This distribution deviates from the 
typical subgroup distribution, with more SP-MS patients. The high number of SP-MS 
patients in our cohort may have occurred because patients had switched from RR-MS 
to SP-MS during the time from disease onset to 1995. In the following years, 
switches to SP-MS continued to occur in the MS patients from the cohort, reinforcing 
the higher proportion of SP-MS patients. Because SP-MS patients are reported to 
have poorer results in cognitive tasks, there is an obvious risk that the dominance of 
SP-MS patients in study II resulted in the MS group performing worse (in comparison 
with the control group) than a more representative group would have. These elements 
of uncertainty concerning the representativeness of the MS sample necessitate caution 
in the interpretation of the results. 
Another methodological limitation was the lack of a control group in studies I, III and 
IV. Instead of comparing with a control group, population-based normative data from 
manuals and handbooks were used in these studies. It is obvious that this is not 
optimal. Because the population-based normative data may have been of varying 
quality, there may have been deficits in the standardization of the test data or the 
normative data may have been too old. However, in the studies undertaken in this 
thesis, normative data from authorized well-reputed manuals and handbooks were 
used. Despite the advantage of having a control group, it would probably have been 
difficult to engage controls for the long follow-up periods in studies I and III. 
When comparing the results of studies I-IV, it is important to keep in mind that the 
MS patient samples were from the same original cohort and were thus not 
independent of each other. A possible consequence of this is that the results of these 
studies could have tendencies in common which might have influenced the 
comparison of results between studies. 
Another weak methodological point in the studies was the insufficient control for 
effects of MS medication.    
Training effects which can appear with retesting using the same task, should also be 
taken into account. These are particularly relevant for those patients who participated 
in all the studies and performed the same test tasks several times. However, the long 
intervals between test and retest, and the use of parallel test versions in the studies, 
probably counterbalanced the influence of training effects to a certain extent. 
Although the test instruments used in studies I-IV have well documented reliability 
(i.e. consistency of the measurements) and validity (i.e. accuracy in the sense that the 
test measures what it is supposed to measure), there is a certain risk that fatigue may 
have contributed to some degree to inconsistencies in the test measures in the MS 
patients. 
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5.7 Concluding remarks 
The main conclusion to be drawn from studies I-IV is that slow IPS appears to be a 
primary aspect of cognitive decline in MS patients. In these studies, deterioration in 
IPS began early in the MS course and predicted long-term cognitive decline. IPS 
could be assumed to be important for the functionality of other domains such as 
language. Cognitive speed in MS was influenced by the neuroradiological 
characteristics as well as membrane turnover of brain cerebrosterol, which interacted 
with the clinico-demographic variables to various degrees. The disease course in MS, 
including the development of cognitive decline, has commonly been viewed as 
primarily driven by neuroinflammation. However, these studies indicate that 
neurodegeneration and the neurotoxic cholesterol oxidation product cerebrosterol also 
independently contribute to cognitive impairment and clinical disability in the 
disease.  
The early cognitive decline, which was seen in the MS patients in study I, seems to be 
selective by occurring in visual IPS rather than auditory IPS and this is a new finding. 
Study II contributes to our understanding of the language pathology in MS, in that 
strategies for lexical substitution and  retrieval were poorer in patients with MS than 
in healthy people and that there was a correlation between the relevance of 
substitutive responses in a naming task and the efficiency of  retrieval strategies in a 
letter fluency task. In study III, the finding that the callosal area, in contrast to the 
RBV and the T2 lesion load, was exclusively associated already initially with 
outcomes of a cognitive speed-demanding task and not with those of sensory-motor 
speed tasks is also a new finding. Similarly, the findings in study IV, that IPS was 
influenced by grey matter volume and plasma cerebrosterol levels and that disability 
measured by the EDSS correlated with plasma cerebrosterol levels are  new. 
With respect to the small sample, caution must be used in interpreting these results. It 
would be fruitful to view the results as preliminary and useful for generating 
hypotheses, with the need for validation in future studies with improved designs and 
larger population samples. Hopefully, these fragments of information can be 
integrated into the cumulated knowledge from earlier research and contribute to 
improved diagnostics as well as a better understanding of cognition in MS.  
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